Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome

Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome

Aims for the study:

  • To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting hepatic steatosis in chronic hepatitis B
  •  To correlate LIVERFASt steatosis with Fibroscan Controlled Attenuation Parameter (CAP) scores

Scroll to Top